Senthil Jdm Pharmacosept Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 53.00%
(FY 2022)
- Profit 110.93%
(FY 2022)
- Ebitda 126.62%
(FY 2022)
- Net Worth 5.90%
(FY 2022)
- Total Assets 55.70%
(FY 2022)
About Senthil Jdm Pharmacosept
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Jadhav and Pritima Dongare serve as directors at the Company.
- CIN/LLPIN
U74999PN2017PTC170872
- Company No.
170872
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Senthil Jdm Pharmacosept?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Jadhav  | Director | 20-Jun-2017 | Current |
| Pritima Dongare | Director | 07-Jun-2017 | Current |
Financial Performance of Senthil Jdm Pharmacosept.
Senthil Jdm Pharmacosept Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 53% increase. The company also saw a substantial improvement in profitability, with a 110.93% increase in profit. The company's net worth moved up by a moderate rise of 5.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Senthil Jdm Pharmacosept?
In 2022, Senthil Jdm Pharmacosept had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shraddha Energy And Infraprojects Private LimitedActive 20 years 1 monthAjay Jadhav is a mutual person
Saburee Agro Seeds Processing Private LimitedActive 5 years 10 monthsAjay Jadhav is a mutual person
- Shraddha Energy & Agro Products Private LimitedActive 12 years 8 months
Ajay Jadhav is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Senthil Jdm Pharmacosept?
Unlock and access historical data on people associated with Senthil Jdm Pharmacosept, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Senthil Jdm Pharmacosept, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Senthil Jdm Pharmacosept's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
